Rapamycin + Prolon Diet for Aging
What You Need to Know Before You Apply
What is the purpose of this trial?
Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death.
Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.
Are You a Good Fit for This Trial?
This trial is for healthy individuals of any sex and ethnicity, aged between 50 to 80 years old. Participants must be able to give informed consent and have stable medical conditions. They may take other medications if they don't interfere with rapamycin.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Prolon Diet, Rapamycin, or a combination of both. The Prolon Diet is administered as a 5-day diet at 0, 1, 2, 3, 4, and 5 months. Rapamycin is given as a 10 mg initial bolus dose followed by a weekly 6 mg dose.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including changes in OMICm methylation and insulin resistance.
Safety Monitoring
Review of adverse reactions to rapamycin and Prolon from baseline to Week 28.
What Are the Treatments Tested in This Trial?
Interventions
- Prolon diet
- Rapamycin
Trial Overview
The REVERSE Study is testing whether Rapamycin tablets and the Prolon diet can impact the aging process. It uses a new age clock based on methylation patterns to measure changes in the rate of aging.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
24 participants: 10 mg initial bolus dose of rapamycin followed by a weekly 6 mg rapamycin along with Prolon 5-day diet at 0, 1, 2, 3, 4,and 5 months. : 12 men, 12 women, 12 ( 6 M, 6 F) who are 50-65 years; 12 ( 6 M, 6 F) who are \>65 years.
12 participants: 10 mg initial bolus dose of rapamycin followed by a weekly 6 mg rapamycin, enrolling 6 men, 6 women, with 6 ( 3 M, 3 F) who are 50-65 years; 6 ( 3 M, 3 F) who are \>65 years
12 participants: 6 men, 6 women, with 6 (3 M, 3 F) who are 50-65 years; 6 who are \>65 years Prolon® 5-day diet at 0, 1, 2, 3, 4 and 5 months;
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Christ Hospital
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.